Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines

Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC. Herein, we address the molecular mechanisms underlying cetuximab resistance in an in vitro mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Izabela N. F., da Silva-Oliveira, Renato J., da Silva, Luciane Sussuchi, Martinho, Olga, Evangelista, Adriane F., van Helvoort Lengert, André, Leal, Letícia Ferro, Silva, Viviane Aline Oliveira, dos Santos, Stéphanie Piancenti, Nascimento, Flávia Caroline, Lopes Carvalho, André, Reis, Rui Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750399/
https://www.ncbi.nlm.nih.gov/pubmed/35011716
http://dx.doi.org/10.3390/cells11010154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750399/
https://www.ncbi.nlm.nih.gov/pubmed/35011716
http://dx.doi.org/10.3390/cells11010154

Ejemplares similares